Skip to main content
Debate: Optimal First-Line Immunotherapy Regimen for HCC: I/O+VEGF vs. I/O Combinations. - I/O+VEGF
Friday, September 24, 2021
12:40 PM – 12:48 PM
Rachna T. Shroff, MD, MS
University of Arizona Cancer Center
This talk is supported by educational grants provided by Bayer HealthCare Pharmaceuticals, Inc., Eisai
Inc., Exelixis, Inc., and Merck Sharp & Dohme Corp.